74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Virbac SA
Open
SectorHealthcare
325 -1.07
Overview
Share price change
24h
Min
324
Max
330
Income | 51M |
|---|---|
Sales | 694M |
P/E Sector Avg | 19.331 34.393 |
EPS | 6.04 |
Dividend yield | 0.43 |
Profit margin | 7.29 |
Employees | 6,365 |
EBITDA | 116M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +11.46% upside |
Dividend yield Sector Avg | 0.43% 2.54% |
|---|---|
Next Earnings | 12 Sept 2025 |
Market Cap | 2.8B |
|---|---|
Previous open | 326.07 |
Previous close | 325 |
News Sentiment
By Acuity
23%
77%
41 / 374 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Virbac SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Virbac SA Forecast
Price Target
By TipRanks
11.46% upside
12 Months Forecast
Average 369.5 EUR 11.46%
High 390 EUR
Low 349 EUR
Based on 2 Wall Street analysts offering 12 month price targets forVirbac SA - Dist in the last 3 months.
Sentiment
By Acuity
41 / 374 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Virbac SA
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
